TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Lapatinib Ditosylate and Radiation Therapy in Treating Patients With Locally Advanced or Locally Recurrent Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with histologically or cytologically confirmed locally advanced breast cancer that is refractory to chemotherapy or other therapeutic agents or with a history of breast cancer with new evidence of a local recurrence (defined as a chest wall or breast recurrence and/or nodal recurrence); the diagnosis will be made based on clinical and pathologic features~* Patients must be \>18 years of age.~* Karnofsky Performance Status (KPS) score \> 70~* Patts must have normal organ function as defined below:~  * total bilirubin \< 1.5 x institutional upper limit of normal~ * AST(SGOT)/ALT(SGPT) \< 2.5 x institutional upper limit of normal~ * creatinine \< 1.5 x institutional upper limit of normal~* Patients must have left-ventricular ejection fraction \> 50% at baseline.~Exclusion Criteria:~* Patients who have contraindications to radiotherapy, such as scleroderma, dermatomyositis, or severe cutaneous manifestations of systemic lupus erythematosus (SLE)~* History of allergic reactions attributed to compounds of similar chemical or biologic composition to lapatinib~* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, or psychiatric illness/social situations that would limit compliance with study requirements~* Women who are pregnant or lactating, as well as women of child-bearing potential who are unwilling or unable to use an acceptable method of birth control to avoid pregnancy for the duration of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lapatinib Plus Radiation Therapy (Type: EXPERIMENTAL): Patients receive lapatinib ditosylate PO QD on day 1 until completion of radiation therapy. Beginning on day 7, patients undergo radiation therapy for 5-7 weeks and will have their blood banked for laboratory biomarker analysis.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Feasibility Study With Patients Who Are at High Risk For Developing Invasive Candidiasis in a Critical Care Setting (MK-0991-067)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Hospitalization for a minimum of 3 days in an ICU and expectation to stay in the ICU for at least another 48 hours~* Meets the following high-risk criteria: Requires mechanical ventilation at the time of study entry; and has a central venous catheter in place at the time of study entry; and is receiving broad spectrum antibiotics at the time of study entry; AND meets at least one of the following criteria: Required parenteral nutrition during the current ICU admission; or required renal dialysis during the current ICU admission; or had major surgery during or within the 7 days before the current ICU admission; or was diagnosed with pancreatitis during or within the 7 days before the current ICU admission; or required systemic steroids or other immunosuppressive agents during or within the 7 days before the current ICU admission~* Meets at least one of the following criteria of suspected infection at the time of study entry or within the 24 hours before study entry: Temperature ≥38° C or ≤36° C (oral equivalent); or hypotension (systolic blood pressure of \<90 mm Hg) or significant drop in blood pressure (40 mm Hg) from the participant's normal baseline; or elevated white blood cell count of ≥12,000/mm\^3~* Candida is growing in at least one non-sterile culture site collected during the current ICU admission~* Female of childbearing potential has a negative serum or urine pregnancy test before enrollment~Exclusion Criteria:~* Females pregnant or breast feeding~* History of allergy, hypersensitivity, or any serious reaction to caspofungin or another member of the echinocandin class (e.g., micafungin, anidulafungin)~* Neutropenia or expected to develop neutropenia during study therapy~* Diagnosis of acquired immune deficiency syndrome (AIDS), aplastic anemia, or chronic granulomatous disease~* Diagnosis of moderate or severe hepatic insufficiency~* Patient not expected to survive at least 24 hours~* Received systemic (IV or oral) antifungal therapy within 10 days before study entry~* Active diagnosis of proven or probable invasive fungal infection (IFI)~* Currently on or has received an investigational agent within 10 days before study entry~* Any condition or concomitant illness which might confuse the study results or pose additional risk in administering the study therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Caspofungin (Type: EXPERIMENTAL): caspofungin acetate
- Placebo (Type: PLACEBO_COMPARATOR): normal saline

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: [S,S]-Reboxetine Add-On Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have pain present for more than 3 months after the healing of shingles skin rash~* Patients at screening must have a score \>/=40 mm on the pain visual analogue scale~Exclusion Criteria:~* Patients with significant renal and hepatic impairment~* Patients with other severe pain, that may impair the self-assessment of the pain due to shingles~* Patients with clinically abnormal electrocardiogram

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- [S,S]-Reboxetine + Pregabalin (Type: EXPERIMENTAL): None
- Pregabalin (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Antiviral Study of ACH-126, 443 (Beta-L-Fd4C) in the Treatment of Adults With Chronic Hepatitis B Infection.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Participants in previous Phase 1 or 2 trials of ACH-126,443 who met entry criteria for previous studies.~* Adults ? 18 years of age~* Chronic HBV infection, known to be HbsAg positive ? 6 months~* Plasma HBV DNA level ? 100,000 copies/mL prior to initiation of ACH-126,443 in an earlier study~* Plasma HBV DNA level that in the medical judgment of the investigator, warrant's antiviral treatment~* HIV negative~* Basic hematologic and chemistry parameters within acceptable limits (defined in protocol)~* No need for excluded medications~* Subjects of reproductive capability must either practice abstinence or utilize two approved forms of birth control, one of which must be barrier protection (condom with spermicidal, diaphragm with spermicidal)~Exclusion Criteria~* HIV infection~* Active Hepatitis C co-infection~* Concurrent systemic antiviral treatment~* Treatment for HBV infection with lamivudine (3TC) for longer than three (3) months since participation in previous trial of ACH-126,443~* Previous therapy with agents with significant systemic myelosuppressive or cytotoxic potential within 3 months of study start or the expected need for such therapy at study start~* Alcohol abuse~* Pregnancy or breast-feeding~* Inability to tolerate oral medication~* AST\>10.0 times the upper limit of normal~* ALT\>10.0 times the upper limit of normal~* Any clinical condition or prior therapy that, in the Investigators opinion, would make the subject unsuitable for the study or unable to comply with the dosing requirements~* Use of investigational drug not approved by Medical Monitor

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Supporting Episodic Memory With Transcranial Direct Current Stimulation in Healthy Controls and Dementia Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent~* Right-handedness~* Non-smokers~* Native German speakers or comparable level of fluency~* Normal or corrected-to-normal vision~Exclusion Criteria:~* Neurological or psychiatric condition (other than diagnosed cognitive impairment)~* Past head injuries~* Magnetizable implants~* History of seizures~* Current or life-time alcohol or drug abuse~* Pregnancy~* Skin diseases

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- Real - sham anodal tDCS (Type: EXPERIMENTAL): Session 1: 20 min of 1 mA anodal tDCS applied via 5x7 cm rubber electrodes over the DLPFC (current density: 0.028 mA/cm2). Additional ramp-up and ramp-down phase at beginning and end of stimulation lasting for 15 s. Electrodes remain attached to the participant's head for the duration of the encoding phase.~Session 2: 30 s of 1 mA anodal tDCS applied via 5x7 cm rubber electrodes over the DLPFC (current density: 0.028 mA/cm2). Additional ramp-up and ramp-down phase at beginning and end of stimulation lasting for 15 s. Electrodes remain attached to the participant's head for the duration of the encoding phase.
- Sham - real anodal tDCS (Type: EXPERIMENTAL): Session 1: 30 s of 1 mA anodal tDCS applied via 5x7 cm rubber electrodes over the DLPFC (current density: 0.028 mA/cm2). Additional ramp-up and ramp-down phase at beginning and end of stimulation lasting for 15 s. Electrodes remain attached to the participant's head for the duration of the encoding phase.~Session 2: 20 min of 1 mA anodal tDCS applied via 5x7 cm rubber electrodes over the DLPFC (current density: 0.028 mA/cm2). Additional ramp-up and ramp-down phase at beginning and end of stimulation lasting for 15 s. Electrodes remain attached to the participant's head for the duration of the encoding phase.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Dexamethasone for Paediatric Adeno-tonsillectomy - A Dose-finding Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria:~* Elective tonsillectomy with or without adenoidectomy with or without eartubes~Exclusion criteria:~* ASA \> II~* Allergie to Dexamethasone~* Recent therapy with steroids or immunotherapy~* Mental retardation~* Children experiencing nausea or vomiting or have taken antiemetic medication within 24 hours before surgery~* Additional surgery~* Enrolement in another investigational study~* Chronic infection or diabetes~* Recent vaccination (less than 1 month prior to surgery)~* Recent varicella infection (less than 1 month prior to surgery)

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 16 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Intravenous dexamethasone 0.05 mg per kg bodyweight
- 2 (Type: ACTIVE_COMPARATOR): Intravenous dexamethasone 0.15 mg per kg bodyweight
- 3 (Type: ACTIVE_COMPARATOR): Intravenous dexamethasone 0.5 mg per kg bodyweight
- 4 (Type: PLACEBO_COMPARATOR): Intravenous saline

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Verapamil vs Steroid to Prevent Keloid Recurrence

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient undergoing surgical removal of keloid~* Patient 18 years old or greater~* Length of excisional scar after surgical removal of keloid between 2 and 10 cm~Exclusion Criteria:~* Keloid in face or hands~* Pregnancy or lactation~* Dementia~* Any heart or pulmonary condition~* Systemic treatment with beta-blockers, ACE-inhibitors or calcium antagonists~* Systemic corticosteroidal therapy~* Intralesional steroid treatment within 2 months of surgery to remove keloid~* Flap surgery~* Lesions to face, hands and other cosmetically sensitive areas

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Verapamil (Type: ACTIVE_COMPARATOR): Verapamil 2.5 mg/mL injection sc intralesionally
- Kenalog 10 (Type: ACTIVE_COMPARATOR): Kenalog 10 mg/mL injection sc intralesionally

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Revitalization of Teeth With Necrotic Pulps and Open Apexes Using Platelet-Rich Plasma

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* People with necrotic pulp and open apex.~Exclusion Criteria:~* People with vital pulp and closed apexes

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 89 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Botulinum Toxin Type A for Neuropathic Pain in Patients With Diabetic Peripheral Polyneuropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: EARLY_PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* • more than twenty years of age~  * patients should have 4 or more items positive among the 10 items of the DN4 questionnaire.~ * persistence of neuropathic pain for more than three months or remission and recurrence of neuropathic pain for more than six months~ * a pain score of 4 or more on the numeric rating scale~Exclusion Criteria:~* • neuropathic pain caused by confounding factors other than diabetic neuropathic pain~  * contraindicated for botulinum toxin type A~ * a change in pain medication one month prior to study enrollment~ * a condition involving neuromuscular junction (Ex. Eaton Lambert disease, myasthenia gravis)~ * person who received botulinum toxin type A within three months prior to study enrollment

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Normal saline (Type: PLACEBO_COMPARATOR): Normal saline
- Botulinum toxin type A 50U (Type: ACTIVE_COMPARATOR): Botulinum toxin 50U
- Botulinum toxin type A 100U (Type: ACTIVE_COMPARATOR): Botulinum toxin 100U

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: N/A

Study Design Characteristics:
- Allocation: N/A
- Intervention Model: N/A
- Observational Model: N/A
- Primary Purpose: N/A
- Time Perspective: N/A
- Masking: N/A
- Phase: N/A
- Number of Arms: N/A

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Trial Using Integuseal as Microbial Sealant for Arterial Bypass Surgery on Lower Extremities

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* planned supragenual of infragenual peripheral arterial bypass procedures with autologue or prosthetic graft~Exclusion Criteria:~* secondary procedures and suprainguinal procedures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- No use of integuseal (Type: NO_INTERVENTION): None
- Use of Integuseal (Type: EXPERIMENTAL): Application of a layer of Integuseal (Cyanoacrylate) from a ready to use applicator preoperative before incision Polymerisation immobilise the bacteria that survived the conventional skin preparation This way there will be les contamination of the wound.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Steroid Treatment for Sickle Cell Pain Crisis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Sickle cell and acute pain Age 8 and up English or Spanish-speaking~Exclusion Criteria:~Fever greater than 101 Acute chest syndrome or pneumonia Other SS complications (sequestration, aplastic crisis) Other explanation for pain (chronic, AVN, surgical) History of GI bleeding, HTN, or hyperglycemia/DM

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Steroid arm (Type: EXPERIMENTAL): Receipt of methyprednisolone pulse dose: 15mg/kg to a maximum of 1 gram; following this, the patients also received a steroid taper with oral prednisone:Day 2: Prednisone 2mg/kg PO BID Day 3: Prednisone 2mg/kg PO daily Day 4: Prednisone 1mg/kg PO daily Day 5: Prednisone 1mg/kg PO daily
- Comparison Group (Type: PLACEBO_COMPARATOR): Patients receiving usual care, with receipt of placebo (saline in lieu of intravenous methylprednisolone infusion or a number of placebo pills equivalent in number to what would have been received for the prednisone.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Lactobacillus Acidophilus and Bifidobacterium Animalis Subsp. Lactis, Maintenance Treatment in Ulcerative Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with ulerative colitis ording to well-known diagnostic criteria and remission for at least one month, and with at least one relapse within the last year.~Exclusion Criteria:~* Pregnancy and lactating~* Serious underlying disease other than UC~* Former gastrointestinal resections~* Medication for UC other than mesalazine~* Known allergic reactions towards compounds in the study drug.~* Expected lack of compliance due to mental state or language problems

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Combination Therapy With Fludarabine, Mitoxantrone and Rituximab in Mantle Cell Lymphoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Pathologic diagnosis of Non-Hodgkin's Lymphoma of the mantle cell sub-type lymphoma only, as determined by morphologic assessment and consistent immunophemotypic markers~* Newly diagnosed and patients who have received prior treatment are eligible~* Measurable or evaluable disease~* Karnofsky performance status greater or equal to 50%~* Men and women, age greater or equal to 18 years old~* AGC greater or equal to 1.0; platelets greater or equal to 75,000; Hemoglobin greater or equal to 8.0 (unless because of lymphomatous infiltration of the marrow)~* Creatinine less than 2.0; bilirubin less than 2.0; SGOT less than 3 times upper limit of normal (unless elevations are due to lymphomatous involvement)~* Women of child bearing potential must have negative pregnancy test within 14 days of study entry.~* Signed informed consent~Exclusion Criteria:~* History of congestive heart failure or significant cardiac disease~* Prior exposure to either fludarabine or mitoxantrone. Prior exposure to rituximab allowed~* Active infection~* HIV seropositive~* Pregnant or lactating females~* Second active malignancy, other than squamous cell skin cancer,in-situ cervical cancer, or history of other cancer diagnosed within the preceding 5 years~* Presence of psychological or emotional disorders which would make valid informed consent impossible

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues